<DOC>
	<DOCNO>NCT00724971</DOCNO>
	<brief_summary>To assess tolerability initial safety profile Inotuzumab Ozogamicin ( CMC-544 ) combination Rituximab patient B-Cell Non-Hodgkin 's lymphoma ( NHL ) .</brief_summary>
	<brief_title>Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin ( CMC-544 ) And Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>CD20 CD22positive , Bcell NHL progress 1 2 prior therapy . Prior therapy must contain least one dose Rituximab therapy . Patients refractory Rituximab ( refractory = PD treatment within 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status : 0/ 1 . Patients must receive previous radioimmunotherapy . Patients tolerant Rituximab . Patients must receive chemotherapy , cancer immunosuppressive therapy , growth factor ( except erythropoietin ) , investigational agent within 28 day first dose test article . Candidate potentially curative therapy Subjects must receive previous radioimmunotherapy . Subjects autologous hematopoietic stem cell transplant within last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>B-cell Non-Hodgkin 's Lymphoma</keyword>
	<keyword>NHL</keyword>
</DOC>